CV Sciences, Inc. (CVSI) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CV Sciences, Inc. (CVSI) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 42/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026CV Sciences, Inc. (CVSI) Resumen de Asistencia Médica y Tuberías
CV Sciences, Inc. develops and markets hemp-based CBD products and plant-based dietary supplements under brands like PlusCBD, targeting the nutraceutical, beauty, and pet sectors. It also develops cannabinoid-based pharmaceuticals, positioning itself in both the consumer wellness and specialty drug markets within the healthcare industry.
Tesis de Inversión
CV Sciences, Inc. presents a speculative investment thesis centered on its dual approach to the cannabinoid market through consumer products and pharmaceutical development. The company's established consumer product lines, generating a gross margin of 47.0%, provide a revenue base to fund its pharmaceutical endeavors. The development of CVSI-007, targeting smokeless tobacco addiction, represents a high-risk, high-reward opportunity. The company's small market capitalization of $0.01 billion and negative P/E ratio of -4.99 indicate substantial risk. Successful clinical trials and subsequent commercialization of CVSI-007 could drive significant value. However, regulatory hurdles, competition, and the need for additional capital are potential risks. Investors should closely monitor clinical trial outcomes, regulatory developments, and the company's ability to maintain market share in the competitive CBD consumer product market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.01 billion, reflecting its status as a micro-cap company.
- Negative P/E ratio of -4.99, indicating that the company is currently unprofitable.
- Gross margin of 47.0%, showcasing the potential profitability of its consumer product segment.
- Beta of 0.19, suggesting lower volatility compared to the overall market.
- Focus on developing CVSI-007, a pharmaceutical drug candidate for smokeless tobacco addiction, highlighting its commitment to innovation.
Competidores y Pares
Fortalezas
- Established brand presence in the CBD market.
- Diverse product portfolio across multiple health sectors.
- Dual focus on consumer products and pharmaceutical development.
- Proprietary drug candidate CVSI-007.
Debilidades
- Small market capitalization and limited financial resources.
- Negative profitability and reliance on external funding.
- Dependence on regulatory environment for CBD products.
- Limited market share compared to larger competitors.
Catalizadores
- Upcoming: Clinical trial results for CVSI-007 in smokeless tobacco addiction treatment.
- Ongoing: Expansion of the PlusCBD product line into new retail channels.
- Ongoing: Development of new CBD-based products for specific health conditions.
- Ongoing: Geographic expansion into international markets.
- Ongoing: Potential strategic acquisitions of complementary businesses.
Riesgos
- Potential: Regulatory changes impacting the CBD market.
- Potential: Delays or failures in clinical trials for CVSI-007.
- Ongoing: Intense competition in the CBD market.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: Fluctuations in raw material prices.
Oportunidades de crecimiento
- Expansion of the PlusCBD product line into new retail channels: CV Sciences can expand its reach by securing partnerships with major retail chains and online marketplaces. The global nutraceutical market is projected to reach $441.7 billion by 2026, offering a significant opportunity for increased sales. Timeline: Ongoing.
- Development and commercialization of CVSI-007: Successful clinical trials and regulatory approval of CVSI-007 for smokeless tobacco addiction could create a significant revenue stream. The market for smoking cessation products is estimated at $8.7 billion globally. Timeline: 3-5 years, contingent on clinical trial results and regulatory approvals.
- Geographic expansion into international markets: CV Sciences can explore opportunities to expand its consumer product sales into international markets, particularly in Europe and Asia, where the demand for CBD products is growing. The European CBD market is projected to reach $1.5 billion by 2027. Timeline: 2-3 years.
- Strategic acquisitions of complementary businesses: CV Sciences can consider acquiring smaller companies with innovative products or technologies in the CBD or nutraceutical space to expand its product portfolio and market reach. The M&A activity in the cannabis industry remains active. Timeline: Opportunistic.
- Development of new CBD-based products for specific health conditions: CV Sciences can invest in research and development to create new CBD-based products targeting specific health conditions, such as anxiety, sleep disorders, and pain management. The market for CBD-based health products is expanding rapidly. Timeline: Ongoing.
Oportunidades
- Expansion into new geographic markets.
- Development of new CBD-based products for specific health conditions.
- Strategic partnerships and acquisitions.
- Successful commercialization of CVSI-007.
Amenazas
- Intense competition in the CBD market.
- Regulatory uncertainty and potential changes in CBD regulations.
- Fluctuations in raw material prices.
- Potential delays or failures in clinical trials for CVSI-007.
Ventajas competitivas
- Established brand recognition with PlusCBD and other brands.
- Proprietary formulations and manufacturing processes.
- Focus on both consumer products and pharmaceutical development.
- Distribution network through multiple channels.
Acerca de CVSI
CV Sciences, Inc., established in 2010 and based in San Diego, California, operates as a life science company in North America. Initially known as CannaVest Corp., the company rebranded in January 2016 to reflect its focus on cannabinoid-based products. CV Sciences is structured into two primary segments: Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under various brand names, including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. These products cater to diverse health care sectors, including nutraceuticals, beauty care, specialty foods, and pet products. The company distributes its consumer products through its websites, internet sales channels, select distributors, brick-and-mortar retailers, and e-tailers. The Specialty Pharmaceutical segment is dedicated to the development and commercialization of cannabinoids for treating medical indications. Its lead drug candidate, CVSI-007, combines CBD and nicotine for the treatment of smokeless tobacco use and addiction, representing the company's foray into pharmaceutical applications of cannabinoids. CV Sciences aims to leverage its expertise in both consumer wellness and pharmaceutical development to establish a strong presence in the cannabinoid market.
Qué hacen
- Develops and markets plant-based dietary supplements.
- Manufactures and sells hemp-based cannabidiol (CBD) products.
- Operates in the nutraceutical, beauty care, specialty foods, and pet product sectors.
- Sells products through websites, internet sales, distributors, retailers, and e-tailers.
- Develops cannabinoid-based pharmaceuticals for medical indications.
- Focuses on CVSI-007, a drug candidate for smokeless tobacco addiction.
Modelo de Negocio
- Develops and manufactures CBD and plant-based products.
- Sells products directly to consumers through online channels.
- Distributes products through retail partnerships.
- Develops pharmaceutical drugs based on cannabinoids.
Contexto de la Industria
CV Sciences operates within the rapidly evolving cannabis and CBD industry. The market is characterized by increasing consumer acceptance of CBD products for wellness applications and growing interest in cannabinoid-based pharmaceuticals. The industry faces regulatory uncertainty and intense competition from both established players and new entrants. CV Sciences' dual focus on consumer products and pharmaceutical development positions it to capitalize on both the immediate demand for CBD products and the long-term potential of cannabinoid-based therapies. Competitors include companies like AUSAF, AYRWF, AYURF, BQST, and BUDZ, all vying for market share in the cannabis and CBD space.
Clientes Clave
- Consumers seeking plant-based dietary supplements.
- Individuals interested in hemp-based CBD products for wellness.
- Retailers and distributors in the nutraceutical and beauty industries.
- Patients seeking cannabinoid-based pharmaceuticals (future).
Finanzas
Gráfico e información
Precio de la acción de CV Sciences, Inc. (CVSI): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Lows On Friday
· 28 feb 2020
-
Stocks That Hit 52-Week Lows On Thursday
· 27 feb 2020
-
Stocks That Hit 52-Week Lows On Friday
· 6 dic 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CVSI.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CVSI.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CVSI en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Joseph D. Dowling
Unknown
Information on Joseph D. Dowling's background is not available in the provided context. Further research would be needed to provide details on his career history, education, and previous roles.
Historial: Information on Joseph D. Dowling's track record is not available in the provided context. Further research would be needed to provide details on key achievements, strategic decisions, and company milestones under his leadership.
Información del mercado OTC de CVSI
The OTC Other tier represents the lowest tier of the OTC market, indicating that CV Sciences, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to listed securities.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and regulatory oversight.
- Lower trading volume and liquidity compared to listed stocks.
- Potential for price manipulation and fraud.
- Higher risk of delisting or trading suspension.
- Greater difficulty in obtaining accurate and timely information.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and funding needs.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- Established business operations with a history of revenue generation.
- Presence of a functioning website and investor relations materials.
- Independent auditor review of financial statements (if available).
- Active engagement with shareholders and the investment community.
- Development of a proprietary drug candidate (CVSI-007).
Acciones de CV Sciences, Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar CVSI?
CV Sciences, Inc. (CVSI) actualmente tiene una puntuación IA de 42/100, indicando puntuación baja. Fortaleza clave: Established brand presence in the CBD market.. Riesgo principal a monitorear: Potential: Regulatory changes impacting the CBD market.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CVSI?
CVSI actualmente puntúa 42/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CVSI?
Los precios de CVSI se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CVSI?
La cobertura de analistas para CVSI incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CVSI?
Las categorías de riesgo para CVSI incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory changes impacting the CBD market.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CVSI?
La relación P/E para CVSI compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CVSI sobrevalorada o infravalorada?
Determinar si CV Sciences, Inc. (CVSI) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CVSI?
CV Sciences, Inc. (CVSI) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited or less reliable than exchange-listed data.
- AI analysis pending for CVSI.